DocumentRX-7798
Issued
Read2 min

FDA Rejects Ivonescimab; J&J Bets $3.3B on Eye Biotech Ollin

FDA rejects ivonescimab for lung cancer; J&J to acquire Ollin Biosciences for up to $3.3B. Also: Teva settles price-fixing case, CMS approves nine devices in 2027 rule.

TAG P-6323 · 493 words on the filing

Recon: FDA rejects ivonescimab for lung cancer indication; J&J to buy eye disease biotech Ollin Biosciences for up to $3
Recon: FDA rejects ivonescimab for lung cancer indication; J&J to buy eye disease biotech Ollin Biosciences for up to $3PublicDomainPictures / pixabay

Summary of findings

  • FDA rejected ivonescimab for a lung cancer indication
  • J&J to buy Ollin Biosciences for up to $3.3 billion
  • CDER's OTS and OCP issued a new MAPP on clinical pharmacology good review practices for NDAs and BLAs
  • CMS 2027 hospital payment final rule approves nine devices and expands outpatient surgery coverage
  • Teva settled US states' drug price-fixing case

The FDA has rejected ivonescimab for a lung cancer indication, while Johnson & Johnson has agreed to buy eye-disease biotech Ollin Biosciences for up to $3.3 billion. Those two headline moves anchor this week's regulatory roundup, which spans CDER review policy, EU combination-product procedure, Medicaid implementation and a shifting medtech M&A posture.

What does the new FDA review manual change?

FDA's Office of Translational Sciences (OTS) and Office of Clinical Pharmacology (OCP), both under the Center for Drug Evaluation and Research, released a new manual of procedures and policies (MAPP — FDA's internal rulebook for staff). It spells out good review practices (GRP) for the clinical pharmacology review of new drug applications and biologics license applications.

Short version: CDER is codifying how its clinical pharmacology reviewers should work NDAs and BLAs. For sponsors, that means a clearer, published standard against which review quality and consistency can be judged.

What happened in Baltimore?

At the AFDO/RAPS Combination Products Summit in Baltimore, a panel of European regulators and industry representatives discussed how to streamline the regulatory process for combination products in the EU. Drug-device hybrids remain one of the slowest categories to clear on both sides of the Atlantic, and the session pointed to procedural simplification as the near-term fix.

What moved in Congress and the agencies?

Washington produced a crowded docket this week:

  • Teva settled US states' drug price-fixing case, closing a major antitrust overhang for the generics giant.
  • HHS is funneling funding and research toward ibogaine and other psychedelics, with Mark Cuban's involvement.
  • Senators introduced a bill to curb conflicts of interest on the preventive care panel.
  • Enforcement of stringent Medicaid work requirements was delayed for six months, giving states a compliance runway.
  • A bipartisan push is possible to curb Trump tariffs, according to MedTech Dive.
  • Democrats are coalescing around 'Medicare for More' and 'Medikids' proposals, STAT reports.
  • Senator-elect Abdul El-Sayed spoke on restoring trust in science, the state of public health, and RFK Jr.

The Medicaid delay is the most operationally significant item. Six months changes state budget planning, not just filing calendars.

What about medtech and food safety?

On Q3 earnings calls, medtech majors favored spin-offs and tuck-ins over big buys — a capital-allocation signal worth tracking for anyone holding supplier or distributor positions. Separately, CMS expanded outpatient surgery coverage and approved nine devices in its 2027 hospital outpatient payment final rule, a concrete win for device makers with ambulatory-surgery economics.

On the food side, the FDA is investigating two new Salmonella outbreaks, and the EU reported on the food safety situation in potential member states — enlargement-linked surveillance that will shape import checks.

What's the takeaway?

The through-line this week is regulatory housekeeping with commercial teeth: a rejected filing, a $3.3 billion acquisition, a price-fixing settlement and a payment rule approving nine devices all land directly on pipeline and portfolio decisions.

via Regulatory Focus (Google News) (Source)

Share this article:

More from Daniel Okafor

Daniel Okafor

Show full bio

Correspondent covering technology and product news in global pharmaceutical industry at PharmInsider.

5 articles

Linked filings

  1. P-6437
  2. K-1065
  3. C-4460
  4. E-4696
  5. K-1653

« Previous filingNext filing »